Investment
Features
FeesSafety
Academy
More
Pluang+

High Templar reports H1 2026 net income of RMB417M amid business transition and share repurchases.

Company Fundamentals
14 Oct 2026
PRNewsWire
View Source
Neutral
High Templar reports H1 2026 net income of RMB417M amid business transition and share repurchases.

High Templar Tech Limited announced a net income of RMB416.9 million (US$61.4 million) for the first half of 2026, down slightly from the previous year due to winding down its last-mile delivery business. Total revenues dropped 72.7% to RMB8.0 million (US$1.2 million), while operating costs fell 10%. The company maintained a strong cash position with RMB3.8 billion in cash and equivalents and continued its share repurchase program, buying back 223.4 million ADSs worth about US$902.5 million. The company is also addressing tax issues related to historical equity restructurings, which may impact future financials. High Templar remains focused on business transition and new opportunities to create long-term shareholder value.

High Templar Tech Limited's first half 2026 financial results provide context for market watchers. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 14, 2026 16:01 WIB: Of 150 priced Technology-sector US stocks tradable on Pluang, 64 rose and 76 fell today. Notable movers include WDC (Western Digital Corp) at USD 372.63 with a 1-day change of -2.12% and Pluang order activity showing 65% Sell / 35% Buy, APPN (Appian Corp) at USD 39.48 up 1.99%, and ATOM (Atomera Incorporated) at USD 3.87 up 1.84% with 100% Buy order activity.

More News

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, contin...

Others
Bullish
1 hour ago
Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...

Market News
Bullish
2 hours ago
FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...

Market News
Bullish
2 hours ago
DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...

Company Fundamentals
Neutral
2 hours ago
Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App